|
1
|
Garg K, Maurer M, Griss J, Brüggen MC,
Wolf IH, Wagner C, Willi N, Mertz KD and Wagner SN: Tumor
associated B cells in cutaneous primary melanoma and improved
clinical outcome. Hum Pathol. Apr 20–2016.pii:
S0046-8177(16)30043-0. doi: 10.1016/j.humpath.2016.03.022 (Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Naldi L, Altieri A, Imberti GL, Giordano
L, Gallus S and La Vecchia C: Cutaneous malignant melanoma in
women. Phenotypic characteristics, sun exposure, and hormonal
factors: A case-control study from Italy. Ann Epidemiol.
15:545–550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shi CH, Wang H, Mao CY, Yang J, Song B,
Liu YT, Yang ZH, Luo HY, Zhang SY, Wu J, et al: MC1R variants in
Chinese Han patients with sporadic Parkinsons disease. Neurobiol
Aging. 42:217.e5–217.e6. 2016. View Article : Google Scholar
|
|
4
|
Pasquali E, García-Borrón JC, Fargnoli MC,
Gandini S, Maisonneuve P, Bagnardi V, Specchia C, Liu F, Kayser M,
Nijsten T, et al: M-SKIP Study Group: MC1R variants increased the
risk of sporadic cutaneous melanoma in darker-pigmented Caucasians:
a pooled-analysis from the M-SKIP project. Int J Cancer.
136:618–631. 2015.PubMed/NCBI
|
|
5
|
Aoude LG, Wadt KA, Pritchard AL and
Hayward NK: Genetics of familial melanoma: 20 years after CDKN2A.
Pigment Cell Melanoma Res. 28:148–160. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gibney GT, Messina JL, Fedorenko IV,
Sondak VK and Smalley KS: Paradoxical oncogenesis - the long-term
effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol.
10:390–399. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Prickett TD, Wei X, Cardenas-Navia I, Teer
JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A,
et al: Exon capture analysis of G protein-coupled receptors
identifies activating mutations in GRM3 in melanoma. Nat Genet.
43:1119–1126. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shoushtari AN and Carvajal RD: GNAQ and
GNA11 mutations in uveal melanoma. Melanoma Res. 24:525–534. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Geertsen R, Hofbauer G, Kamarashev J, Yue
FY and Dummer R: Immune escape mechanisms in malignant melanoma.
Int J Mol Med. 3:49–57. 1999.PubMed/NCBI
|
|
10
|
Serrone L and Hersey P: The
chemoresistance of human malignant melanoma: An update. Melanoma
Res. 9:51–58. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luan J, Shattuck-Brandt R, Haghnegahdar H,
Owen JD, Strieter R, Burdick M, Nirodi C, Beauchamp D, Johnson KN
and Richmond A: Mechanism and biological significance of
constitutive expression of MGSA/GRO chemokines in malignant
melanoma tumor progression. J Leukoc Biol. 62:588–597.
1997.PubMed/NCBI
|
|
12
|
Hussussian CJ, Struewing JP, Goldstein AM,
Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA and
Dracopoli NC: Germline p16 mutations in familial melanoma. Nat
Genet. 8:15–21. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ha L, Ichikawa T, Anver M, Dickins R, Lowe
S, Sharpless NE, Krimpenfort P, Depinho RA, Bennett DC, Sviderskaya
EV, et al: ARF functions as a melanoma tumor suppressor by inducing
p53-independent senescence. Proc Natl Acad Sci USA.
104:10968–10973. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Busch C, Geisler J, Knappskog S, Lillehaug
JR and Lønning PE: Alterations in the p53 pathway and p16INK4a
expression predict overall survival in metastatic melanoma patients
treated with dacarbazine. J Invest Dermatol. 130:2514–2516. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Howell PM Jr, Liu S, Ren S, Behlen C,
Fodstad O and Riker AI: Epigenetics in human melanoma. Cancer
Control. 16:200–218. 2009.PubMed/NCBI
|
|
16
|
Klose RJ and Bird AP: Genomic DNA
methylation: the mark and its mediators. Trends Biochem Sci.
31:89–97. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Straume O, Smeds J, Kumar R, Hemminki K
and Akslen LA: Significant impact of promoter hypermethylation and
the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the
vertical growth phase. Am J Pathol. 161:229–237. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Spugnardi M, Tommasi S, Dammann R, Pfeifer
GP and Hoon DS: Epigenetic inactivation of RAS association domain
family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer
Res. 63:1639–1643. 2003.PubMed/NCBI
|
|
19
|
Mirmohammadsadegh A, Marini A, Nambiar S,
Hassan M, Tannapfel A, Ruzicka T and Hengge UR: Epigenetic
silencing of the PTEN gene in melanoma. Cancer Res. 66:6546–6552.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miura S, Maesawa C, Shibazaki M, Yasuhira
S, Kasai S, Tsunoda K, Maeda F, Takahashi K, Akasaka T and Masuda
T: Immunohistochemistry for histone h3 lysine 9 methyltransferase
and demethylase proteins in human melanomas. Am J Dermatopathol.
36:211–216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tiffen J, Gallagher SJ and Hersey P: EZH2:
an emerging role in melanoma biology and strategies for targeted
therapy. Pigment Cell Melanoma Res. 28:21–30. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kappelmann M, Kuphal S, Meister G,
Vardimon L and Bosserhoff AK: MicroRNA miR-125b controls melanoma
progression by direct regulation of c-Jun protein expression.
Oncogene. 32:2984–2991. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang J, Na S, Liu C, Pan S, Cai J and Qiu
J: MicroRNA-125b suppresses the epithelial-mesenchymal transition
and cell invasion by targeting ITGA9 in melanoma. Tumour Biol.
37:5941–5949. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rigel DS and Carucci JA: Malignant
melanoma: Prevention, early detection, and treatment in the 21st
century. CA Cancer J Clin. 50:215–236, 237–240. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han D, Zager JS, Shyr Y, Chen H, Berry LD,
Iyengar S, Djulbegovic M, Weber JL, Marzban SS, Sondak VK, et al:
Clinicopathologic predictors of sentinel lymph node metastasis in
thin melanoma. J Clin Oncol. 31:4387–4393. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khalil DN and Carvajal RD: Treatments for
noncutaneous melanoma. Hematol Oncol Clin North Am. 28:507–521.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Russo A, Ficili B, Candido S, Pezzino FM,
Guarneri C, Biondi A, Travali S, McCubrey JA, Spandidos DA and
Libra M: Emerging targeted therapies for melanoma treatment
(review). Int J Oncol. 45:516–524. 2014.PubMed/NCBI
|
|
28
|
Russo AE, Torrisi E, Bevelacqua Y,
Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F and
Malaponte G: Melanoma: molecular pathogenesis and emerging target
therapies (Review). Int J Oncol. 34:1481–1489. 2009.PubMed/NCBI
|
|
29
|
Garbe C, Eigentler TK, Keilholz U,
Hauschild A and Kirkwood JM: Systematic review of medical treatment
in melanoma: current status and future prospects. Oncologist.
16:5–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xin Y, Huang Q, Zhang P, Yang M, Hou XY,
Tang JQ, Zhang LZ and Jiang G: Meta-analysis of the safety and
efficacy of interferon combined with dacarbazine versus dacarbazine
alone in cutaneous malignant melanoma. Medicine (Baltimore).
95:e34062016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hartman ML and Czyz M: MITF in melanoma:
Mechanisms behind its expression and activity. Cell Mol Life Sci.
72:1249–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vandamme N and Berx G: Melanoma cells
revive an embryonic transcriptional network to dictate phenotypic
heterogeneity. Front Oncol. 4:3522014. View Article : Google Scholar : PubMed/NCBI
|
